Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival?
Sassu,C. M.,Marchetti,C.,Russo,G.,Minucci,A.,Boccia,S. M.,Benato,A.,Nero,C.,Piermattei,A.,Mattogno,P. P.,Giannarelli,D.,Ferrandina,G.,Olivi,A.,Fagotti,A.,Scambia,G.
DOI: https://doi.org/10.1136/ijgc-2023-004980
2024-01-06
International Journal of Gynecological Cancer
Abstract:Objective To evaluate disease characteristics and survival according to BRCA status, administration of poly-(ADP-ribose) polymerase inhibitors (PARPi), and surgery in patients with ovarian cancer and brain metastases. Methods This is a monocentric retrospective cohort of patients with ovarian cancer and brain metastases treated between 2000 and 2021. Data were collected by a retrospective review of medical records and analyzed according to: (1) BRCA mutation; (2) PARPi before and after brain metastases; (3) surgery for brain metastases. Results Eighty-five patients with ovarian cancer and brain metastasis and known BRCA status (31 BRCA mutated ( BRCA m), 54 BRCA wild-type ( BRCA wt)) were analyzed. Twenty-two patients had received PARPi before brain metastases diagnosis (11 BRCA m, 11 BRCA wt) and 12 after (8 BRCA m, 4 BRCA wt). Brain metastases occurred >1 year later in patients who had received previous PARPi. Survival was longer in the BRCA m group (median post-brain metastasis survival: BRCA m 23 months vs BRCA wt 8 months, p=0.0015). No differences were found based on BRCA status analyzing the population who did not receive PARPi after brain metastasis (median post-brain metastasis survival: BRCA m 8 months vs BRCA wt 8 months, p=0.31). In the BRCA m group, survival was worse in patients who had received previous PARPi (median post-brain metastasis survival: PARPi before, 7 months vs no-PARPi before, 24 months, p=0.003). If PARPi was administered after brain metastases, survival of the overall population improved (median post-brain metastasis survival: PARPi after, 46 months vs no-PARPi after, 8 months, p=0.00038). In cases of surgery for brain metastases, the prognosis seemed better (median post-brain metastasis survival: surgery 13 months vs no-surgery 8 months, p=0.036). Three variables were significantly associated with prolonged survival at multivariate analysis: BRCA mutation, multimodal treatment, and ≤1 previous chemotherapy line. Conclusions BRCA mutations might impact brain metastasis occurrence and lead to better outcomes. In a multimodal treatment, surgery seems to affect survival even in cases of extracranial disease. PARPi use should be considered as it seems to prolong survival if administered after brain metastasis.
oncology,obstetrics & gynecology